Medical electronics manufacturing is being shaped by the convergence of connected devices, compact electronics, and new ways to perform diagnostic testing. For engineers and operations teams, this creates opportunities to rethink where and how health measurements are made. It also raises practical demands: devices must be manufacturable, repeatable, and supported by quality processes appropriate to their intended use.
One emerging concept is to bring some laboratory functions closer to the patient or point of care. Turning that concept into a viable product takes more than miniaturizing electronics. It requires coordination among device designers, electronics manufacturers, quality teams, and other stakeholders from early development through production.
Connected healthcare and the lab-on-a-chip concept
A lab-on-a-chip aims to combine functions associated with a biomedical laboratory in a compact device. A sample such as blood or urine can be analyzed without relying on the same sequence of collection, transport to a central laboratory, and return of results. The intended benefit is to make testing more accessible in settings where laboratory facilities may be distant or unavailable, while also supporting applications such as disease diagnosis and treatment monitoring.
Researchers have explored building these systems using printed circuit board (PCB) processes. In a lab-on-PCB design, the board can carry electronic functions alongside microfluidic channels—small pathways that move liquids through the device. This approach connects medical diagnostics with established electronics manufacturing methods. However, it is not simply a conventional PCB with different components: designers must account for fluid handling and biological analysis as well as electrical operation.
Lab-on-PCB development is still an evolving field. Unlike conventional PCB design, it does not yet have a widely established library of microfluidic components and standardized design rules. Designers may need to adapt existing software and develop component representations and checks for the fluidic features. That makes collaboration between electronics, biomedical, and manufacturing specialists particularly important.
Medical electronics manufacturing starts with design collaboration
Early engagement with an electronics manufacturing services (EMS) provider can help identify production concerns before a design is fixed. An EMS partner can review a proposed product for design for manufacturability (DFM), design for assembly (DFA), and design for test (DFT). These reviews may consider component pad geometry, PCB panelization, mechanical integration, test access, and whether specified tolerances are achievable.
For a complete device, the manufacturing discussion may extend beyond the printed circuit board assembly (PCBA). Displays, enclosures, plastics, metals, hardware, and other subassemblies may need to be integrated. Reviewing these elements together can help reveal assembly or test constraints that would be harder to address after production has begun.
A structured new product introduction (NPI) process is also important. Prototypes and phased production provide opportunities to assess whether the design can be built consistently before moving into broader manufacturing. Compressing this work to meet a target launch date may leave less time to identify and resolve process or design issues. The practical goal is not simply a fast handoff to production, but a product and process that can deliver repeatable results.
Quality systems and regulatory considerations
Medical device manufacturing operates within defined quality and regulatory frameworks. The specific obligations depend on the product, its intended use, and the markets in which it will be sold. An EMS provider may manufacture a device without being responsible for its design or regulatory submissions, but it still needs processes that support the customer’s applicable requirements.
ISO 13485 is a quality management standard specifically associated with medical devices. U.S. requirements also include the FDA’s Quality System Regulation, 21 CFR Part 820, and requirements concerning electronic records and signatures under 21 CFR Part 11. The relevant controls can involve documentation, process validation, software validation, traceability, and records of device history. Requirements may also vary by jurisdiction.
For diagnostic devices, cleanliness and contamination control can be significant manufacturing considerations. Repeatability and reliability matter because the device is used in a medical context, and allowable variation may differ from that accepted in other applications. Requirements for sterilization or other controls depend on the product; they should be addressed during development rather than assumed to be a late-stage manufacturing detail.
Plan for test, components, and supply continuity
Testability should be considered while the product is being designed. Providing appropriate access for in-circuit testing and planning for functional test can help manufacturers evaluate assemblies before and after system integration. This is particularly relevant when a product combines a PCBA with mechanical and fluid-handling elements.
Component availability is another development and production concern. Long lead times or obsolescence can affect schedules and product continuity. A bill-of-materials review can help teams identify components that may warrant closer attention and consider suitable alternatives when necessary. For medical products, sourcing decisions also need to account for component authenticity; working through authorized sources where possible and using established controls for other sourcing routes helps manage counterfeit risk.
Build a production-ready connected device
Connected healthcare technologies may change how diagnostic information is gathered and where testing can take place. But product adoption depends on more than an innovative concept. Lab-on-PCB devices, like other medical electronics, must bring together sound design, manufacturable construction, appropriate testing, documented quality processes, and supply-chain planning.
For engineering and operations teams, the practical implication is clear: involve manufacturing and quality expertise early, define regulatory responsibilities, and treat NPI as a way to prove the production process—not merely as a step on the path to launch. That foundation helps teams move from a promising medical electronics concept toward a device that can be built consistently and supported in its intended healthcare setting.